Ipilimumab augments antitumor activity of bispecific antibody-armed T cells

详细信息    查看全文

• 作者：Hiroshi Yano ; Archana Thakur ; Elyse N Tomaszewski…
• 关键词：Ipilimumab ; Cytotoxic T ; lymphocyte antigen ; 4 (CTLA ; 4) ; Bispecific antibody ; Pancreatic cancer ; Colorectal cancer ; Burkitt’s lymphoma ; Activated T cells ; Immunotherapy
• 刊名：Journal of Translational Medicine
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：12
• 期：1
• 全文大小：1,614 KB
• 参考文献：1. Kalathil, S, Lugade, AA, Miller, A, Iyer, R, Thanavala, Y (2013) Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res 73: pp. 2435-2444 CrossRef
  2. Suarez, N, Alfaro, C, Dubrot, J, Palazon, A, Bolanos, E, Erro, L, Hervas-Stubbs, S, Martinez-Forero, I, Morales-Kastresana, A, Martin-Algarra, S, Sangro, B, Lecanda, F, Perez-Gracia, JL, Gonzalez, A, Melero, I (2011) Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo. International Journal of Cancer 129: pp. 374-386 CrossRef
  3. Maszyna, F, Hoff, H, Kunkel, D, Radbruch, A, Brunner-Weinzierl, MC (2003) Diversity of clonal T cell proliferation is mediated by differential expression of CD152 (CTLA-4) on the cell surface of activated individual T lymphocytes. J Immunol 171: pp. 3459-3466 CrossRef
  4. Jago, CB, Yates, J, Camara, NO, Lechler, RI, Lombardi, G (2004) Differential expression of CTLA-4 among T cell subsets. Clin Exp Immunol 136: pp. 463-471 CrossRef
  5. Linsley, PS, Nadler, SG, Bajorath, J, Peach, R, Leung, HT, Rogers, J, Bradshaw, J, Stebbins, M, Leytze, G, Brady, W, Malacko, AR, Marquardt, H, Shaw, SY (1995) Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules. The Journal of Biological Chemistry 270: pp. 15417-15424 CrossRef
  6. van der Merwe, PA, Bodian, DL, Daenke, S, Linsley, PS, Davis, SJ (1997) CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics. J Exp Med 185: pp. 393-404 CrossRef
  7. Peggs, KS, Quezada, SA, Korman, AJ, Allison, JP (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18: pp. 206-213 CrossRef
  8. Walunas, TL, Lenschow, DJ, Bakker, CY, Linsley, PS, Freeman, GJ, Green, JM, Thompson, CB, Bluestone, JA (2011) Pillars article: CTLA-4 Can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-13. J Immunol 187: pp. 3466-3474
  9. Krummel, MF, Allison, JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182: pp. 459-465 CrossRef
  10. Leach, DR, Krummel, MF, Allison, JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: pp. 1734-1736 CrossRef
  11. Fecci, PE, Ochiai, H, Mitchell, DA, Grossi, PM, Sweeney, AE, Archer, GE, Cummings, T, Allison, JP, Bigner, DD, Sampson, JH (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13: pp. 2158-2167 CrossRef
  12. Sorensen, MR, Holst, PJ, Steffensen, MA, Christensen, JP, Thomsen, AR (2010) Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine 28: pp. 6757-6764 CrossRef
  13. Sutmuller, RP, van Duivenvoorde, LM, van Elsas, A, Schumacher, TN, Wildenberg, ME, Allison, JP, Toes, RE, Offringa, R, Melief, CJ (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194: pp. 823-832 CrossRef
  14. Hodi, FS, O'Day, SJ, McDermott, DF, Weber, RW, Sosman, JA, Haanen, JB, Gonz
• 刊物主题：Biomedicine general; Medicine/Public Health, general;
• 出版者：BioMed Central
• ISSN：1479-5876

文摘

Background Ipilimumab is an antagonistic monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4) that enhances antitumor immunity by inhibiting immunosuppressive activity of regulatory T cells (Treg). In this study, we investigated whether inhibiting Treg activity with ipilimumab during ex vivo T cell expansion could augment anti-CD3-driven T cell proliferation and enhance bispecific antibody (BiAb)-redirected antitumor cytotoxicity of activated T cells (ATC). Methods PBMC from healthy individuals were stimulated with anti-CD3 monoclonal antibody with or without ipilimumab and expanded for 10-14 days. ATC were harvested and armed with anti-CD3 x anti-EGFR BiAb (EGFRBi) or anti-CD3 x anti-CD20 BiAb (CD20Bi) to test for redirected cytotoxicity against COLO356/FG pancreatic cancer cell line or Burkitt’s lymphoma cell line (Daudi). Results In PBMC from healthy individuals, the addition of ipilimumab at the initiation of culture significantly enhanced T cell proliferation (p--.0029). ATC grown in the presence of ipilimumab showed significantly increased mean tumor-specific cytotoxicity at effector:target (E:T) ratio of 25:1 directed at COLO356/FG and Daudi by 37.71% (p--.0004) and 27.5% (p--.0004), respectively, and increased the secretion of chemokines (CCL2, CCL3, CCL4,CCL5, CXCL9, and granulocyte-macrophage colony stimulating factor(GM-CSF)) and cytokines (IFN-γ, IL-2R, IL-12, and IL-13), while reducing IL-10 secretion. Conclusions Expansion of ATC in the presence of ipilimumab significantly improves not only the T cell proliferation but it also enhances cytokine secretion and the specific cytotoxicity of T cells armed with bispecific antibodies.